On Friday, Allegheny Technologies Incorporated (NYSE:ATI)’s shares inclined 0.25% to $28.12.
Allegheny Technologies Incorporated (ATI) will provide live Internet listening access to its conference call with investors and analysts planned for Tuesday, July 21, 2015 at 8:30 a.m. ET. The conference call will be conducted after the Company’s planned release of second quarter 2015 results. The conference call will be broadcast, and accompanying presentation slides will be accessible, at www.ATImetals.com. To access the broadcast, go to the home page and select “Conference Call”. Replay of the conference call will be accessible on the ATI website.
Allegheny Technologies Incorporated produces and sells specialty materials and components worldwide. The company operates through two segments, High Performance Materials and Components; and Flat-Rolled Products. The High Performance Materials and Components segment provides various high performance materials, counting titanium and titanium-based alloys; nickel-and cobalt-based alloys and superalloys; zirconium and related alloys, such as hafnium and niobium, advanced powder alloys, and other specialty materials, in long product forms of ingots, billets, bars, rods, wires, shapes and rectangles, and seamless tubes, plus precision forgings, castings, components, and machined parts.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s shares gained 1.10% to $141.67.
BioMarin Pharmaceutical Inc. (BMRN) recently declared the U.S. Food and Drug Administration (FDA) has accepted for review the submission of a New Drug Application (NDA) for drisapersen for the treatment of Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping, and the Prescription Drug User Fee Act (PDUFA) aim date for a decision is December 27, 2015. The FDA has granted drisapersen Priority Review status, which is designated to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists.
In the FDA’s filing communication, the Agency informed the company that it is presently planning to hold an advisory committee meeting to talk about the application. No date has been set for this meeting. Drisapersen formerly has been granted Orphan and Fast Track status, in addition to Breakthrough Therapy designations by the FDA. The U.S. filing is based on three randomized placebo-controlled trials and two long-term open-label studies of more than 300 patients in which some boys have been treated for more than three years.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products comprise Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease.
At the end of Friday’s trade, Jacobs Engineering Group Inc (NYSE:JEC)‘s shares surged 0.78% to $40.15.
Jacobs Engineering Group Inc (JEC) declared it was designated by Managing Contractor Lend Lease Building Pty Limited for a major extension to an existing contract for the New Air Combat Capability (NACC) facilities project in Australia.
The NACC project is developing new and refurbished facilities on ten Defence sites around Australia to accommodate the Royal Australian Air Force’s introduction of the new Joint Strike Fighter (JSF) F-35A Lightning jets.
Under the terms of the contract extension, Jacobs is providing design services encompassing structural, security, electrical, mechanical, civil, traffic, hydraulic, fire and acoustics.
Company officials did not disclose the contract value.
Jacobs Engineering Group Inc. provides technical, professional, and construction services to various industrial, commercial, and governmental clients. It offers project services that comprise engineering, design, architectural, interiors, planning, environmental, and other services; and process, scientific, and systems consulting services, counting services performed in connection with scientific testing, analysis, and consulting activities, in addition to information technology, and systems engineering and integration activities.
SolarCity Corp (NASDAQ:SCTY), ended its Friday’s trading session with 1.96% gain, and closed at $53.00.
SolarCity (SCTY) declared energy storage for new homes and a special low, fixed-rate solar power offering for California homebuilders and their buyers.
Founded in 2011, the SolarCity Homebuilder Program presently works with builders across the nation to give many new home buyers the option to add solar power systems without increasing the home’s purchase price, and pay less for solar electricity than they would otherwise pay for utility power. SolarCity also handles everything from design and installation to monitoring and repairs.
SolarCity Corporation designs, manufactures, installs, maintains, monitors, leases, and sells solar energy systems to residential, commercial, government, and other customers in the United States. It offers solar energy systems; solar lease and power purchase agreement finance products; mounting hardware for photovoltaic panels; and related software, in addition to develops a proprietary battery administration system, which is designed to enable remote, bidirectional control of distributed energy storage that can provide benefits to customers, utilities, and grid operators. The company also sells electricity generated by solar energy systems to customers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
